Intech Investment Management LLC Lowers Stock Holdings in IDEAYA Biosciences, Inc. $IDYA

Intech Investment Management LLC decreased its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 34.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,491 shares of the company’s stock after selling 20,390 shares during the quarter. Intech Investment Management LLC’s holdings in IDEAYA Biosciences were worth $830,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of the company. State of New Jersey Common Pension Fund D boosted its position in IDEAYA Biosciences by 11.1% during the second quarter. State of New Jersey Common Pension Fund D now owns 100,827 shares of the company’s stock valued at $2,119,000 after buying an additional 10,047 shares during the period. Oppenheimer Asset Management Inc. boosted its holdings in IDEAYA Biosciences by 19.3% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 13,787 shares of the company’s stock valued at $290,000 after acquiring an additional 2,227 shares during the period. American Century Companies Inc. bought a new position in IDEAYA Biosciences during the 1st quarter worth approximately $195,000. Signaturefd LLC increased its stake in IDEAYA Biosciences by 58.1% in the 2nd quarter. Signaturefd LLC now owns 4,549 shares of the company’s stock worth $96,000 after purchasing an additional 1,672 shares during the period. Finally, Swiss National Bank increased its stake in IDEAYA Biosciences by 0.8% in the 1st quarter. Swiss National Bank now owns 150,800 shares of the company’s stock worth $2,470,000 after purchasing an additional 1,200 shares during the period. Hedge funds and other institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Trading Up 1.1%

IDEAYA Biosciences stock opened at $35.88 on Thursday. The firm has a market cap of $3.15 billion, a price-to-earnings ratio of -19.29 and a beta of 0.14. The stock has a fifty day simple moving average of $29.66 and a two-hundred day simple moving average of $25.02. IDEAYA Biosciences, Inc. has a 12 month low of $13.45 and a 12 month high of $36.55.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Tuesday, November 4th. The company reported $1.33 earnings per share for the quarter, beating the consensus estimate of ($0.12) by $1.45. The company had revenue of $207.83 million for the quarter, compared to analysts’ expectations of $59.98 million. On average, equities research analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

IDYA has been the topic of several recent analyst reports. Mizuho raised their target price on shares of IDEAYA Biosciences from $44.00 to $46.00 and gave the stock an “outperform” rating in a report on Tuesday, November 11th. BTIG Research reaffirmed a “buy” rating and issued a $62.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, October 21st. Oppenheimer set a $36.00 price objective on IDEAYA Biosciences and gave the company an “outperform” rating in a research report on Monday, September 8th. JPMorgan Chase & Co. increased their target price on IDEAYA Biosciences from $74.00 to $79.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a research report on Tuesday, September 9th. Fifteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $46.40.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.